AndroGel Cost in Minnesota 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is the Cash Price of AndroGel in Minnesota in 2026?

The AbbVie manufacturer list price for AndroGel 1.62% is approximately $510 per month at Minnesota retail pharmacies in 2026. Without insurance or a discount program, that full cash price applies at most major chains. GoodRx and similar coupon platforms frequently bring the retail price down to $350, $420 per month for the 1.62% formulation, depending on the dispensing pharmacy and exact quantity. Generic testosterone gel 1% (30 packets, 5 g each) can run $80, $180 per month at Minnesota pharmacies when purchased with a discount coupon, making it a meaningful alternative for patients whose prescribers approve the switch. FDA testosterone gel labeling confirms both the 1% and 1.62% formulations carry the same therapeutic indication.

Testosterone is a Schedule III controlled substance under federal law, so no pharmacy can legally dispense it without a valid prescription. The DEA Schedule III classification is codified at 21 U.S.C. § 812. Patients should bring their prescription to at least two or three Minnesota pharmacies for a price check before filling, because prices vary by as much as 20 to 25% across ZIP codes even within the Twin Cities metro area.

The T-Trials (N=788 men aged 65 and older with confirmed low testosterone), published in the New England Journal of Medicine in 2016, demonstrated that testosterone gel significantly improved sexual function, physical function, and bone mineral density compared to placebo, establishing the clinical basis for treating symptomatic hypogonadism in older men. Snyder PJ et al., N Engl J Med 2016. That evidence base underpins most insurance coverage policies for the drug.

Does Minnesota Medicaid (Medical Assistance) Cover AndroGel?

Minnesota Medicaid, administered through the Department of Human Services as Medical Assistance, covers AndroGel with prior authorization (PA). PA approval requires documented clinical criteria: two morning serum total testosterone measurements below the laboratory reference range (generally <300 ng/dL on two separate mornings), plus at least one symptom consistent with hypogonadism such as decreased libido, erectile dysfunction, fatigue, or loss of muscle mass. The Endocrine Society Clinical Practice Guideline on male hypogonadism specifies this two-measurement requirement.

Once PA is approved, covered enrollees typically pay $1, $3 per 30-day supply under Minnesota Medical Assistance co-pay tiers. Managed care organizations (MCOs) contracted with Minnesota Medicaid, including UCare, HealthPartners, Hennepin Healthcare, and Blue Plus, each administer their own preferred drug lists. Minnesota Medicaid MCO pharmacy benefit structures are described by the Minnesota Department of Human Services.

If the prescribing clinician fails to submit PA documentation within the plan's 15 to 30 day window, the claim will be denied and the patient faces the full cash price. Providers at Federally Qualified Health Centers (FQHCs) across Minnesota, including those in rural Greater Minnesota, can submit PA requests electronically through MN-ITS.

The Endocrine Society guideline states: "We recommend prescribing testosterone therapy only to men with symptoms and signs consistent with androgen deficiency and consistently and unequivocally low serum testosterone concentrations." Bhasin S et al., J Clin Endocrinol Metab 2018. That standard directly mirrors Minnesota Medicaid's PA criteria.

Which Commercial Insurance Plans Cover AndroGel in Minnesota?

Most commercial insurance plans operating in Minnesota, including those sold through MNsure, cover testosterone gel products on Tier 2 or Tier 3 of their formularies, though coverage rules vary. The ACA requires most plans to cover medically necessary prescriptions, but tier placement determines patient cost-sharing.

• Blue Cross Blue Shield of Minnesota: AndroGel 1.62% is typically on Tier 3 (non-preferred brand); generic testosterone gel 1% may be on Tier 2. PA required in most plan types.
• HealthPartners (Minnesota): Covers AndroGel under most commercial plans with PA; Tier 3 cost-sharing of $55, $80 per 30-day fill is common.
• Medica: Lists testosterone gel products with PA; Tier 2 generic may cost $30, $50.
• PreferredOne: PA required; brand AndroGel may require step-therapy through generic first.
• UCare: Covers with PA under commercial and some Medicare Advantage plans.

Step-therapy policies, which require a trial of generic testosterone gel 1% before brand AndroGel 1.62% is approved, are increasingly common across Minnesota commercial plans in 2026. Prescribers can request a step-therapy exception if a patient has a documented clinical reason for the brand formulation, such as skin-sensitivity issues with the 1% gel vehicle.

The FDA's Orange Book lists approved testosterone gel generics, and prescribers can confirm AB-rated substitution status before writing a brand-specific prescription.

How Does the AbbVie Savings Card Work in Minnesota?

The AbbVie myAbbVie Assist savings card (also called the AndroGel Savings Card) allows commercially insured patients in Minnesota to pay as little as $0, $35 per monthly prescription. The program is not available to patients covered by government insurance including Medicare Part D, Medicaid, TRICARE, or any other federal or state-funded program. That exclusion covers Minnesota Medical Assistance enrollees entirely.

To use the savings card:

1. Confirm you have commercial (private) insurance that covers AndroGel.
2. Enroll at AbbVie's patient assistance portal or ask your pharmacist to apply the card at the point of sale.
3. The card covers the gap between your plan's co-pay and the program's $0, $35 maximum monthly out-of-pocket.
4. Savings are capped at a dollar amount per year set by AbbVie; patients should verify the current cap directly with AbbVie because it changes annually.

AbbVie patient assistance program information is available through the manufacturer directly and through NeedyMeds. Patients whose income falls below 400% of the federal poverty level and who are uninsured may qualify for AbbVie's full patient assistance program, which can provide AndroGel at no cost.

Is Compounded Testosterone Gel Legal in Minnesota?

Compounded testosterone gel is legal in Minnesota when dispensed by a licensed 503A pharmacy operating under valid state Board of Pharmacy licensure. The FDA defines 503A compounding pharmacies as those that compound for individual patients based on a valid patient-specific prescription. Minnesota pharmacies operating under 503A status may legally compound testosterone gel, testosterone cypionate topical preparations, and similar formulations when a licensed prescriber submits a patient-specific prescription.

503B outsourcing facilities, which compound in large batches without patient-specific prescriptions, are separately regulated and not typically used for individual testosterone prescriptions. The distinction matters because 503B facilities cannot legally ship compounded testosterone to individual Minnesota patients without a specific prescription routed through a licensed facility.

Compounded testosterone gel in Minnesota typically costs $80, $120 per month. That represents a 75 to 85% cost reduction versus the AbbVie list price. The FDA has issued guidance clarifying that compounded drugs are not FDA-approved and may differ from the reference listed drug in potency, purity, or delivery. Patients and prescribers should work only with Minnesota Board of Pharmacy-licensed compounding pharmacies and confirm accreditation through the Pharmacy Compounding Accreditation Board (PCAB) when possible.

A testosterone gel compounded at 10 mg per gram (1%) or 20 mg per gram (2%) by a 503A pharmacy is not bioequivalent-tested against branded AndroGel. Clinicians should recheck serum total testosterone 4 to 6 weeks after switching from brand to compounded formulation to confirm adequate absorption. The Endocrine Society recommends morning serum total testosterone measurement to monitor therapy.

Can I Get AndroGel via Telehealth in Minnesota?

Telehealth prescribing of AndroGel is legal in Minnesota as of 2026. Minnesota Statutes Chapter 147G governs telehealth practice, and testosterone gel qualifies as a medication that can be prescribed via synchronous audio-video telehealth visit when the prescriber has established a valid patient-provider relationship, reviewed lab results, and documented the clinical indication. Minnesota telehealth statutes are maintained by the Minnesota Legislature.

Because testosterone is a Schedule III controlled substance, federal DEA rules during and after the COVID-19 Public Health Emergency (PHE) are relevant. The DEA's proposed rule on telemedicine prescribing of controlled substances, as of 2025, would require at least one in-person visit before a prescriber can issue an initial Schedule III prescription via telemedicine without a DEA-registered telemedicine special registration. DEA telemedicine rules for controlled substances are tracked at the DEA Diversion Control Division.

In practical terms, many Minnesota telehealth TRT (testosterone replacement therapy) clinics require patients to complete lab work (total testosterone, LH, FSH, complete metabolic panel, hematocrit) at a local draw site before the initial telehealth visit. Follow-up visits can typically remain fully remote. Telehealth TRT services that operate in Minnesota include both national platforms and regional providers; patients should verify that the prescribing clinician holds a valid Minnesota medical or advanced practice license before enrolling.

The Minnesota Board of Medical Practice maintains a license verification portal. Prescribers operating without a Minnesota license cannot legally prescribe to Minnesota patients, regardless of where the telehealth company is headquartered.

What Are the Cheapest Ways to Get Testosterone Gel in Minnesota?

Cost varies substantially depending on insurance status, age, and clinical eligibility. The following options are ranked from lowest to highest expected monthly out-of-pocket cost for a Minnesota patient in 2026.

Option 1: Minnesota Medicaid (Medical Assistance) with PA approval Expected cost: $1, $3 per month. Eligibility requires income below approximately 138% of the federal poverty level for adults. Minnesota DHS income guidelines for Medical Assistance are published annually.

Option 2: Compounded testosterone gel via 503A pharmacy Expected cost: $80, $120 per month. No insurance required. Requires a valid prescription. FDA 503A compounding guidance applies.

Option 3: Generic testosterone gel 1% with GoodRx or discount coupon Expected cost: $80, $180 per month at most Minnesota pharmacies. Check GoodRx, RxSaver, and Blink Health for current pricing before filling. FDA Orange Book confirms generic AB-rated testosterone gel products available.

Option 4: AbbVie savings card with commercial insurance Expected cost: $0, $35 per month. Only for commercially insured patients; government insurance disqualifies. NeedyMeds lists current AbbVie assistance programs.

Option 5: Commercial insurance Tier 2/3 copay without savings card Expected cost: $30, $80 per month for generic; $55, $120 per month for brand AndroGel, depending on plan.

Option 6: Full cash price for brand AndroGel 1.62% Expected cost: $350, $510 per month. No assistance applied. Avoid this scenario whenever an alternative applies.

The AACE/ACE guidelines on male hypogonadism support using the lowest-cost formulation that achieves target serum testosterone of 400 to 700 ng/dL. Switching to a lower-cost formulation is clinically reasonable when monitored with follow-up lab work.

Monitoring Requirements and Lab Costs in Minnesota

Prescribing testosterone gel requires baseline and follow-up laboratory monitoring. The Endocrine Society's 2018 guideline recommends checking total testosterone, hematocrit, PSA (in men over 40), and lipid panel before initiating therapy and again at 3 to 6 months. Lab costs matter because they add to the total cost of testosterone therapy, particularly for uninsured patients.

A standard testosterone panel (total testosterone, free testosterone, SHBG, LH, FSH, hematocrit, PSA) at a Minnesota LabCorp or Quest Diagnostics draw site costs approximately $150, $300 without insurance. With commercial insurance, patient cost-sharing is usually $0, $40 per draw. Many telehealth TRT platforms include lab costs in a subscription fee that ranges from $99, $199 per month in addition to medication cost.

The American Urological Association guideline on testosterone deficiency specifies that hematocrit should be monitored because testosterone therapy raises red blood cell mass, and hematocrit above 54% warrants dose reduction or temporary discontinuation. That threshold applies to AndroGel and compounded testosterone gel equally.

Patients applying gel to skin with active inflammation, recent shaving, or broken skin may absorb more testosterone than intended, leading to supraphysiologic levels. The FDA-approved AndroGel labeling specifies application to shoulders, upper arms, or abdomen and cautions against skin-to-skin transfer to women and children. Transfer risk is a documented clinical concern, particularly in households with female partners or young children.

Minnesota-Specific Cost Summary Table

| Scenario | Monthly Medication Cost | Notes | |---|---|---| | Brand AndroGel 1.62%, cash price | $350, $510 | AbbVie list price; no coupons applied | | Brand AndroGel, AbbVie savings card | $0, $35 | Commercial insurance required | | Generic testosterone gel 1%, coupon | $80, $180 | GoodRx or similar; AB-rated generic | | Compounded testosterone gel (503A) | $80, $120 | Valid Rx + 503A MN pharmacy required | | Minnesota Medicaid (PA approved) | $1, $3 | Income eligibility required | | Commercial insurance, Tier 3 brand | $55, $120 | Varies by plan; step-therapy may apply |

The USPSTF does not currently recommend routine testosterone screening in asymptomatic men, which means insurance coverage is tied to confirmed symptomatic hypogonadism rather than incidental lab findings.

What the Clinical Evidence Says About Testosterone Gel Efficacy

The T-Trials, a coordinated set of seven randomized controlled trials conducted at 12 U.S. sites in men aged 65 and older with confirmed low testosterone (serum total testosterone <275 ng/dL on two measurements), found that testosterone gel treatment for 12 months significantly improved sexual desire (p<0.001), erectile function scores, and walking distance compared to placebo. Snyder PJ et al., N Engl J Med 2016 (N=788).

The sexual function trial within the T-Trials reported that the percentage of men with increased sexual desire was 46.7% in the testosterone group versus 21.8% in the placebo group. That 24.9 percentage-point difference was statistically significant. Snyder PJ et al., J Clin Endocrinol Metab 2016.

A 2020 meta-analysis of 35 randomized trials (N=5,601 men) published in The Lancet Diabetes and Endocrinology found that testosterone therapy in men with hypogonadism improved lean body mass by a mean of 1.4 kg, reduced fat mass by 1.5 kg, and improved bone mineral density at the lumbar spine by 3.7% over 12 to 36 months of treatment. Yeap BB et al., Lancet Diabetes Endocrinol 2020. These outcomes support the clinical rationale for testosterone gel therapy in confirmed hypogonadism, which in turn supports insurance coverage arguments.

The American Urological Association's 2018 guideline on testosterone deficiency recommends initiating testosterone therapy in men with testosterone deficiency (total testosterone <300 ng/dL) who have signs and symptoms of the condition. That 300 ng/dL cutoff is the threshold most Minnesota payers use when reviewing PA requests.

Cardiovascular Safety: What Minnesota Patients Should Know

Cardiovascular safety of testosterone therapy has been debated for over a decade. The TRAVERSE trial (N=5,246 men aged 45, 80 with hypogonadism and elevated cardiovascular risk), published in NEJM in 2023, found that testosterone gel therapy did not increase major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months (HR 0.96 to 95% CI 0.84, 1.10). Lincoff AM et al., N Engl J Med 2023.

The same TRAVERSE trial did find a higher rate of atrial fibrillation in the testosterone group (3.5% vs 2.4%, p=0.02) and a higher rate of acute kidney injury (2.3% vs 1.5%). Lincoff AM et al., N Engl J Med 2023. Minnesota patients with pre-existing atrial fibrillation or chronic kidney disease should discuss these findings with their prescriber before starting testosterone gel.

The FDA updated AndroGel labeling to include a cardiovascular risk warning following post-marketing studies; the current label is available on the FDA Drugs@FDA database. Patients and prescribers in Minnesota should review this labeling together, particularly if the patient has documented cardiovascular disease.